PATENT CLAIM ANALYSIS

Application Number: 16109562
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-08
Patent Classification: ["514", "290000"]

Abstract:
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

Claim (Index 3):
The method of  claim 1 , wherein R 1  is selected from the group consisting of hydrogen, alkyl, substituted alkyl, halo, alkoxy, aryloxy, substituted aryloxy, substituted aryl, alkylthio, aminoacyl, aryl, substituted amino, heteroaryl, heteroaryloxy, \u2014S(O) n -aryl, \u2014S(O) n -substituted aryl, \u2014S(O) n -heteroaryl, and \u2014S(O) n -substituted heteroaryl, where n is zero, one or two.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 96.0
- Lexical Diversity: 1.16
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10861082', '15133104', '12015275', '11442727', '13599161']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8491173699631724
- 35 USC 102 Novelty (BERT): 0.6182832913731733
- Combined Prediction Score: 0.8260339621041725
- Mean Citation Score: 509.981424
- Max Citation Score: 539.677
- Similarity Product: 535.6993258070946

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test